News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
Poviztra is a second brand of Wegovy
The said inspection concluded with Zero Form 483 observation
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Subscribe To Our Newsletter & Stay Updated
